NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in ...

Please provide your email address to receive an email when new articles are posted on . A London-based biotech firm has announced a collaboration and licensing agreement with a Japanese pharmaceutical ...

Researchers discover how ribosomes contribute to the recognition and removal of RNA crosslinking damage. Aldehydes are toxic compounds that are produced in the body by metabolic processes, especially ...

LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the ...

Eli Lilly signed a deal to use MiNA Therapeutics’ small activating RNA platform to develop drug candidates against up to five targets, the companies announced May 11. Under the deal, Eli Lilly will ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...

NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in ...

Aldehydes are toxic compounds that are produced in the body by metabolic processes, especially upon alcohol consumption. They are dangerous because they bind to cellular macromolecules such as DNA, ...

The MarketWatch News Department was not involved in the creation of this content. NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA ...